Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – showed that nearly two-thirds (61.6%) of patients with brain metastases ...

Hello. At this time, I would like to welcome everyone to the Exact Sciences. Third quarter, 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to Erik ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Liberty Media Corp. Series C Liberty Formula One 1.13% $24.38B Liberty Media Corp. Series A Liberty Formula One 1.37% $24.38B Liberty Broadband Corp. Cl A 1.00% $13.84B Liberty Broadband Corp. Cl ...

Greetings, and welcome to the Incyte third-quarter financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn ...

AGNC Investment Corp. Dep. Pfd. (Rep. 6.875% Cum. Redeem. Pfd. Series D 0.24% AGNC Investment Corp. Dep. Pfd. (Rep. 1/1000th Pfd. Series C) 0.41% AGNC Investment Corp ...

Regarding our cell cycle portfolio, we have been closely tracking the emerging datasets, including those shared at ESMO, that continue to validate the promise of targeting CDK2. We are nearing the ...

An S corp is an organization that has chosen to pass its tax burden to its shareholders, rather than report income, losses, deductions and credits directly to the Internal Revenue Service (IRS).

One method that is gaining traction is the S corporation election. This strategy has the potential to help business owners alleviate employment taxes and foster financial success. The concept of ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC ...

During the quarter, we also provided important clinical updates at ESMO with encouraging data for our CDK2 inhibitor in ovarian and endometrial cancer as well as data from the Phase 3 trial of ...